OKYO Pharma Announces Public Offering of Ordinary Shares

Summary by AI BETAClose X

OKYO Pharma Limited announced its intention to conduct an underwritten public offering of ordinary shares, with the company selling all shares and granting the underwriter a 30-day option to purchase an additional 15%. The net proceeds are intended for clinical development of product candidates, general corporate purposes, and working capital. This offering is subject to market conditions, and there is no assurance regarding its completion, size, or terms. The company recently completed a Phase 2 trial for urcosimod and plans to initiate a Phase 2b/3 study in the first half of the year.

Disclaimer*

UK 100

Latest directors dealings